Copyright
©The Author(s) 2015.
World J Cardiol. Jun 26, 2015; 7(6): 344-350
Published online Jun 26, 2015. doi: 10.4330/wjc.v7.i6.344
Published online Jun 26, 2015. doi: 10.4330/wjc.v7.i6.344
Characteristic | All study participants n = 265 | Participants without primary endpoint event1n = 216 | Participants with primary endpoint event1n = 49 | P value2 |
Age, mean ± SD, yr | 57.4 ± 10.7 | 57.5 ± 10.6 | 57.2 ± 11.3 | 0.848 |
Male sex | 230 (86.8%) | 185 (85.6%) | 45 (91.8%) | 0.350 |
Cardiovascular risk factors | ||||
Hypertension | 152 (57.4%) | 124 (57.4%) | 28 (57.1%) | 0.973 |
Dyslipidemia | 161 (60.8%) | 131 (60.6%) | 30 (61.2%) | 0.941 |
Diabetes mellitus | 60 (22.6%) | 49 (22.7%) | 11 (22.4%) | 0.972 |
Smoking3 | 154 (58.1%) | 121 (56.0%) | 33 (67.3%) | 0.147 |
Family history of CAD | 81 (30.6%) | 65 (30.1%) | 16 (32.7%) | 0.725 |
Cardiac disease | ||||
CAD | 152 (57.4%) | 120 (55.6%) | 32 (65.3%) | 0.213 |
DCM | 58 (21.9%) | 45 (20.8%) | 13 (26.5%) | 0.384 |
HCMObstructiveNon-obstructive | 1 (0.4%)3 (1.1%) | 1 (0.5%)2 (0.9%) | 0 (0.0%)1 (2.0%) | 1.0000.460 |
Brugada syndrome | 2 (0.8%) | 2 (0.9%) | 0 (0.0%) | 1.000 |
Long QT | 3 (1.1%) | 3 (1.4%) | 0 (0.0%) | 1.000 |
Other cardiac disease | 30 (11.3%) | 26 (12.0%) | 4 (8.2%) | 0.618 |
Echocardiography | ||||
LVEF, mean ± SD | 41.1% ± 15.9% | 42.8% ± 16.2% | 33.6% ± 11.7% | < 0.001 |
LVEF < 35% | 106 (40.0%) | 79 (36.6%) | 27 (55.1%) | 0.017 |
EPS | ||||
Induction of sustained VT | 125 (47.2%) | 91 (42.1%) | 34 (69.4%) | 0.001 |
Induction of non-sustained VT | 60 (22.6%) | 53 (24.5%) | 7 (14.3%) | 0.122 |
No VT induction | 80 (30.2%) | 72 (33.3%) | 8 (16.3%) | 0.019 |
Predictor variable | Sensitivity | Specificity | PPV | NPV | AUROC (95%CI) |
Primary endpoint | |||||
Sustained VT during EPS | |||||
All study participants (n = 265) | 69.4% | 57.9% | 27.2% | 89.3% | 0.636 (0.563-0.709) |
Subgroup of study participants with LVEF < 35% (n = 106) | 66.7% | 48.1% | 30.5% | 80.9% | 0.574 (0.468-0.680) |
Subgroup of study participants with LVEF ≥ 35% (n = 159) | 72.7% | 63.5% | 24.2% | 93.5% | 0.681 (0.578-0.785) |
LVEF < 35% | 55.1% | 63.4% | 25.5% | 86.1% | 0.593 (0.515-0.670) |
Secondary endpoint | |||||
Sustained VT during EPS | |||||
All study participants (n = 265) | 66.7% | 55.6% | 17.6% | 92.1% | 0.611 (0.524-0.699) |
Subgroup of study participants with LVEF < 35% (n = 106) | 61.1% | 45.5% | 18.6% | 85.1% | 0.533 (0.406-0.660) |
Subgroup of study participants with LVEF ≥ 35% (n = 159) | 73.3% | 61.8% | 16.7% | 95.7% | 0.676 (0.553-0.798) |
LVEF < 35% | 54.5% | 62.1% | 17.0% | 90.6% | 0.583 (0.491-0.675) |
- Citation: Hilfiker G, Schoenenberger AW, Erne P, Kobza R. Utility of electrophysiological studies to predict arrhythmic events. World J Cardiol 2015; 7(6): 344-350
- URL: https://www.wjgnet.com/1949-8462/full/v7/i6/344.htm
- DOI: https://dx.doi.org/10.4330/wjc.v7.i6.344